leisure time -WSS

leisure time

author：comprehensive 2025-09-28 08:53:49 - browse：4

LONDON — AstraZeneca said Tuesday it would acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on the booming area of targeted radiation therapies for cancer.

AstraZeneca will pay $2 billion in cash upfront for Fusion, a price that at $21 a share is nearly double Fusion’s closing share price on Monday. If certain regulatory milestones are met, AstraZeneca will pay another $3 a share, or roughly $400 million.

Fusion specializes in developing radiopharmaceuticals, also known as radioconjugates or radioligands, which deliver radiation directly to tumors, guided by particular markers on cancer cells. The aim is not only to minimize the risk of damaging surrounding, healthy tissue, but also to reach tumors that traditional radiation can’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： Appeals court upholds limits to abortion pill

WSS

2024 GOP presidential candidates spar over abortion in debate

Apellis safety probe of eye disease drug centers on injection needle

As pharma fights Medicare drug negotiation, hospitals, docs silent

AstraZeneca loses challenge to Medicare drug price negotiation

Study finds new variant for Parkinson’s in African populations

Complete sequence of Y chromosome published for first time

explore

leisure time

knowledge

Sports medicine is finally prioritizing gender equality

AstraZeneca loses challenge to Medicare drug price negotiation

Medicare proposal to cover medical devices draws a mixed reaction

AstraZeneca challenges Medicare drug negotiation program

How to save PrEP access — and even expand it

As pharma fights Medicare drug negotiation, hospitals, docs silent

Medical records are filled with copy

Radiation, mainstay of cancer treatment, begins a fade

Guidelines to prevent youth baseball injuries need more muscle

Drug firms test therapies to halt Alzheimer’s before symptoms arise

focus

Drug firms test therapies to halt Alzheimer’s before symptoms arise

Winners, losers from Medicare’s list of drugs subject to price talks

AstraZeneca challenges Medicare drug negotiation program

How to make Best Hospitals ratings actually useful for patients

International team creates first chimeric human

Psilocybin's anti

hotspot

Wikipedia

Wikipedia

focus